CNS tumors, as an extracolonic manifestation of LS, appear to be relatively infrequent, with the occurrence risk quadrupling, and the cumulative lifetime risk of brain tumors is significantly greater in individuals with MSH2 mutations than in those with variants in other MMR genes28,37,38. The gene discussed is MSH2; the disease is central nervous system neoplasm.